<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04632966</url>
  </required_header>
  <id_info>
    <org_study_id>KOA-20-01</org_study_id>
    <nct_id>NCT04632966</nct_id>
  </id_info>
  <brief_title>Safety Study of PTP-001 for Treating Knee Osteoarthritis</brief_title>
  <official_title>A Prospective, Open-Label, Dose-Escalation Phase 1 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulate (PTP-001) for the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety, tolerability, and efficacy of a single intra-articular (IA) injection&#xD;
      of PTP-001, an allogeneic placental tissue particulate, in individuals with knee&#xD;
      osteoarthritis (OA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, dose-escalation study is expected to enroll 20 participants, 40-80 years of&#xD;
      age and test two doses (low and high dose) of PTP-001, an allogeneic placental tissue&#xD;
      particulate, in two unique cohorts of 10 participants each. Each participant will receive a&#xD;
      single intra-articular (IA) injection of PTP-001. Following the completion of the first&#xD;
      cohort in which 10 participants (Kellgren-Lawrence Grade 2 or 3 knee OA) will be treated with&#xD;
      the low dose of PTP-001, safety data will be reviewed by an independent Data and Safety&#xD;
      Monitoring Board (DSMB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, dose-escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of local and systemic treatment emergent adverse events (AEs) and incidence of abnormal laboratory and immunogenicity panels</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Incidence of local and systemic treatment emergent adverse events (AEs), including clinical laboratory and immunogenicity panels, after a single intra-articular injection of PTP-001.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster University (WOMAC) Pain Responder Rate</measure>
    <time_frame>Week 26 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Physical Function Responder Rate</measure>
    <time_frame>Week 26 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pain of the index knee, by evaluating the WOMAC Pain subscale score (the possible total score ranging from 0-50 for pain)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>WOMAC Numerical Rating Scale (NRS) 3.1 questionnaire is a health status measure questionnaire of 24 questions comprising 3 subscales (pain, stiffness and physical function). WOMAC A (measure of pain) is measured on 11-point NRS ranging from 0 (none) to 10 (extreme), where higher score represents higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in physical function of the index knee, by evaluating the WOMAC Physical Function subscale score (the possible total score ranging from 0-170 for Physical Function)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>WOMAC Numerical Rating Scale (NRS) 3.1 questionnaire is a health status measure questionnaire of 24 questions comprising 3 subscales (pain, stiffness and physical function). WOMAC C (measure of physical function) is measured on 11-point NRS ranging from 0 (none) to 10 (extreme), where higher score represents higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patient global assessment of OA, by assessing the participants assessment of how they are doing considering arthritis in index knee (the possible answers include &quot;Very Good&quot;, &quot;Good&quot;, &quot;Acceptable&quot;, &quot;Poor&quot;, &quot;Very Poor&quot;</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in health-related quality of life, by assessing the items from the Short Form 36 (SF-36) survey</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>The SF-36 measures 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health (the possible total normalized score ranges from 0-100). Higher scores on the SF-36 indicate better health status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in biochemical markers (CTX-II &amp; PRO-C2)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Urinary CTX-II samples&#xD;
Serum PRO-C2 samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in joint space width of the index knee, assessed radiographically (OARSI radiographic scoring)</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>PTP-001 - Low Dose (100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-articular injection of 100 mg PTP-001 resuspended with 4 mL of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTP-001 - High Dose (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intra-articular injection of 200 mg PTP-001 resuspended with 4 mL of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological: PTP-001</intervention_name>
    <description>allogeneic placental tissue particulate</description>
    <arm_group_label>PTP-001 - High Dose (200 mg)</arm_group_label>
    <arm_group_label>PTP-001 - Low Dose (100 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
          -  Male or female, aged 40 to 80 years&#xD;
&#xD;
          -  Symptomatic knee OA with Kellgren-Lawrence radiographic classification of 2 or 3&#xD;
&#xD;
          -  Non-responsive after at least 3 months of conservative therapy for knee OA&#xD;
&#xD;
          -  Females of childbearing potential must have negative pregnancy test result prior to&#xD;
             treatment and must commit to highly effective methods of contraception for at least 6&#xD;
             months after treatment&#xD;
&#xD;
          -  Willingness to report oral analgesic treatment used for knee pain and to discontinue&#xD;
             analgesic treatment for knee pain in 24 hours prior to each study visit&#xD;
&#xD;
          -  Willingness to limit use of pain rescue medication to oral acetaminophen for&#xD;
             management of painful knee OA flare&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 40 kg/m2 or BMI ≥ 35 kg/m2 with condition that warrants weight&#xD;
             loss surgery&#xD;
&#xD;
          -  Presence of active infection of index knee or systemic infection requiring treatment&#xD;
             within 3 months of Screening&#xD;
&#xD;
          -  Administration of IA injection within 3 months of Screening&#xD;
&#xD;
          -  Significant acute injury to index knee within 3 months of Screening&#xD;
&#xD;
          -  Surgery to index knee within 6 months of Screening or planned surgery to index knee&#xD;
             within 6 months after Screening&#xD;
&#xD;
          -  Unstable index knee joint&#xD;
&#xD;
          -  History of radiation therapy of index knee&#xD;
&#xD;
          -  Known vascular or neurological disorder affecting the index knee&#xD;
&#xD;
          -  Osteonecrosis of either knee&#xD;
&#xD;
          -  Clinical diagnosis of inflammatory arthritis&#xD;
&#xD;
          -  Clinical diagnosis of autoimmune disease affecting the musculoskeletal system&#xD;
&#xD;
          -  Use of any other investigational therapy within 3 months of Screening or planned for&#xD;
             the duration of the study&#xD;
&#xD;
          -  Current anti-coagulant use&#xD;
&#xD;
          -  History of receiving a solid organ or hematologic transplant&#xD;
&#xD;
          -  History of malignancy or radiotherapy within 5 years of Screening, except for basal or&#xD;
             squamous cell carcinoma of the skin&#xD;
&#xD;
          -  Use of immunosuppressive or chemotherapeutic agents within 5 years of Screening&#xD;
&#xD;
          -  Known allergy to local anesthetics or allograft tissues&#xD;
&#xD;
          -  Known history of hepatitis&#xD;
&#xD;
          -  Known history of thrombotic or thromboembolic phenomena.&#xD;
&#xD;
          -  Known history of primary or secondary immunodeficiency disorders&#xD;
&#xD;
          -  Presence of concurrent medical condition that, in the investigator's judgement, could&#xD;
             compromise participant safety or interfere with the required study assessments and&#xD;
             study participation.&#xD;
&#xD;
        Note: Other protocol defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annunziato Amendola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James R. Urbaniak, MD, Duke Sports Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drew Sullivan, BS</last_name>
    <phone>919-474-6703</phone>
    <email>drew.sullivan@bioventusglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MK Kottke, PhD</last_name>
    <email>mk.kottke@bioventusglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>James R. Urbaniak, MD, Duke Sports Science Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily K Reinke, PhD</last_name>
      <phone>919-684-8997</phone>
      <email>emily.reinke@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Annunziato Amendola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Morton</last_name>
      <phone>843-352-6977</phone>
    </contact>
    <contact_backup>
      <last_name>Nicole Shebelskie</last_name>
      <phone>843-856-3784</phone>
    </contact_backup>
    <investigator>
      <last_name>Shailesh M. Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flannery CR, Seaman SA, Buddin KE, et al. Characterization and preclinical efficacy of PTP-001, a novel human tissue biologic in development for the treatment of OA. Osteoarthritis Cartilage. 2020 Apr;28(Supplement 1):S487-S489. doi: 10.1016/j.joca.2020.02.763</citation>
  </reference>
  <reference>
    <citation>Flannery CR, Seaman SA, Buddin KE, Nasert MA, Semler EJ, Kelley KL, Long M, Favret J, Pavesio A, Loeser RF. A novel placental tissue biologic, PTP-001, inhibits inflammatory and catabolic responses in vitro and prevents pain and cartilage degeneration in a rat model of osteoarthritis. Osteoarthritis Cartilage. 2021 Aug;29(8):1203-1212. doi: 10.1016/j.joca.2021.03.022. Epub 2021 May 20.</citation>
    <PMID>34023528</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

